<DOC>
	<DOCNO>NCT02181023</DOCNO>
	<brief_summary>- Chronic Obstructive Pulmonary Disease ( COPD ) characterize lung hyperinflation flow limitation . These physiopathological modification secondary loss elastic recoil bronchial obstruction due emphysema . - The cornerstone COPD treatment represent inhaled beta-2 agonist anticholinergic . The molecule latter class characterize short last action ( hour ) , long act action ( 12 hour ) ultra long acting duration action ( 24 hour ) . - For year anticholinergic ( antimuscarinic ) drug use aerosol , Tiotropium Bromide . Recently two new antimuscarinic agent launch market : glycopyrronium bromide ( daily ) aclidinium ( twice daily ) . - The Single Breath Nitrogen Test capable identify pulmonary closing volume . The part curve reflect lung ventilation inhomogeneity slope phase III - For COPD patient , important characteristic inhalatory drug prompt action order give quick relief respiratory symptom , particular dyspnoea . - The objective study study acute action glycopyrronium aclidinium term reduction hyperinflation , pulmonary specific resistance , lung volume distribution dyspnoea rest severe COPD patient . - To knowledge study explored aspect .</brief_summary>
	<brief_title>Acute Effect Aclidinium Hyperinflation Ventilation Inhomogeneity Severe COPD Patients</brief_title>
	<detailed_description>Chronic Obstructive Pulmonary Disease ( COPD ) disease characterize progressive evolutionary physiopathological change responsible develop respiratory symptom , disability , poor quality life morbidity . These change secondary parenchymal disruption chronic bronchiolar inflammation major part due cigarette smoke . Lung architectural derangement loss elastic recoil secondary emphysema together decrease internal bronchiolar lumen due mucosal chronic inflammation responsible bronchial obstruction , flow limitation lung hyperinflation . All feature bring exertional dyspnoea , chronic cough sputum decrease activeness daily life activity . The Single Breath Nitrogen Washout Test ( SBN2 ) one test adequately catch modification small airway premature collapse call closing volume ( CV ) . Together CV test reflect pulmonary ventilation inhomogeneity slope call phase III ( plateau line nitrogen concentration steeper big ventilation inhomogeneity ) . In literature effect COPD inhalatory treatment modification hyperinflation today poorly analyse . Recently new anticholinergic molecule develop , particular Aclidinium Bromide Glycopyrronium Bromide , trace evaluation medical literature new inhalatory drug . The study acute effect drug lung mechanic mandatory quicker effect , faster patient 's dyspnoea relief . The study comprise first enrollment visit suitable subject undergo pharmacological washout 72 hour inhalatory drug except Salbutamol . Then patient randomise give Glycopyrronium Bromide 44 mcg ( matched Aclidinium Bromide 322 mcg placebo ) Aclidinium Bromide 322 mcg ( matched Glycopyrronium Bromide 44 mcg placebo ) ( Day 1 ) double dummy scheme . At day 1 pre-dose ( baseline ) evaluation consist : - body plethysmography ( residual volume specific resistance evaluation ) , - arterial blood gas analysis ( partial pressure oxygen carbon dioxide evaluation ) , - SBN2 - Visual Analogic Scale Dyspnoea ( VAS scale ) evaluation - Diffusion Lung Capacity Carbon Monoxide Single Breath method ( DLCO ) . These test repeat 5 , 15 , 30 , 60 180 minute study drug inhalation . DLCO arterial blood gas analysis perform baseline 180 minute study drug inhalation . After day 1 patient undergo another period inhalatory therapy washout 72 hour ( rescue Salbutamol spray permit ) . After second pharmacological washout patient undergo cross . The one give Aclidinium Bromide assume Glycopyrronium Bromide vice versa ( Day 2 ) always double dummy condition . At Day 2 patient undergo evaluation day 1 . At day 1 day 2 study drug two different device ( active drug + placebo ) give patient medical personnel involve performing test day 1 2 , order maintain double blind condition .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Signature inform consent COPD patient age rag 50 85 year old Patients least history COPD one year COPD patient clinically stable last three month COPD subject Forced Expiratory Volume one second ( FEV1 ) &lt; 50 % predict value COPD subject Residual Volume ( RV ) &gt; 125 % predict value FEV1/Forced Vital Capacity ( FVC ) &lt; 88 % ( male ) &lt; 89 % ( female ) Low Levels Normality ( LLN ) COPD former active smoker least smoke history 20 pack year Acute Bronchial Exacerbation recruitment Fertile woman age 18 50 year old active period Pregnancy Subjects enrol clinical trial take part one month precede enrollment . FEV1/FVC 70 % predict value basal condition FEV1 70 % predict value basal condition Known deficit alpha 1 antitrypsin Subjects underwent Lung Volume Reduction Surgery ( LVRS ) Subjects know positivity Human Immunodeficiency Virus ( HIV ) Misuse alcool drug Lack compliance perform respiratory test Subjects capable follow study prescription psychic disorder language problem . Long Term Oxygen Therapy flow &gt; 6 litre per minute ( l/min ) rest</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>COPD</keyword>
	<keyword>Hyperinflation</keyword>
	<keyword>Aclidinium</keyword>
	<keyword>Glycopyrronium</keyword>
	<keyword>Volume distribution</keyword>
	<keyword>Anticholinergic</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Single Breath Nitrogen Test</keyword>
	<keyword>Phase III</keyword>
</DOC>